Bottom Line: In a comparison of different classes of drugs used to lower blood sugar levels for patients with type 2 diabetes, sodium-glucose cotransporter 2 (SGLT-2) inhibitors or glucagon-like peptide 1(GLP-1) agonists were associated with a lower risk of death than dipeptidyl peptidase 4 (DPP-4) inhibitors or control (placebo or no treatment).
Why The Research Is Interesting: Several drug classes have emerged that are effective in improving blood sugar control for patients with type 2 diabetes, including SGLT-2 and DPP-4 inhibitors and GLP-1 agonists. The clinical effectiveness of these drugs compared to each other is not known.
Who and When: 176,310 study participants with type 2 diabetes in 236 randomized clinical trials in databases through October 2017
What (Study Measures): SGLT-2 inhibitors, GLP-1 agonists, DPP-4 inhibitors, and control (placebo, no treatment) (interventions); death from any cause (outcome).
How (Study Design): This was a network meta-analysis, which combines the results of multiple studies identified in a systematic review and quantitatively summarizes the overall association between interventions and outcomes measured across all studies.
Authors: Sean L. Zheng, B.M., B.Ch., M.A., M.R.C.P., Imperial College Healthcare NHS Foundation Trust, London, and coauthors
Study Limitations: Network meta-analysis respects randomization of clinical trials, but itself represents observational data, preventing conclusions on causality from being inferred.
Study Conclusions: In patients with type 2 diabetes, the use of SGLT-2 inhibitors or GLP-1 agonists was associated with better survival than DPP-4 inhibitors.
Related material: The following related elements also are available on the For The Media website:
-- A summary video is available for download or to embed on your website. Download the video as a high-quality MP4 file by clicking on this link and then right-clicking and selecting "save video as." In addition, you may copy and paste the html code below to embed the video on your website.
For more details and to read the full study, please visit the For The Media website.
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Want to embed a link to this report in your story? Link will be live at the embargo time http://jamanetwork.
Translation available: A translation in simplified Chinese will be available.